Product Code: 2720
Extracorporeal Membrane Oxygenation Market will exceed USD 370.0 million by 2025; as per a new research report.
Rising prevalence of respiratory disorders and growing adoption of extracorporeal membrane oxygenation procedure for the treatment will accelerate the growth of the ECMO market globally. Non-communicable diseases such as cardiovascular and chronic respiratory diseases are the main cause of mortality worldwide. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally.
Growing awareness about cardiovascular and respiratory conditions among the people and rising demand for better treatment procedures are the key factors propelling market growth for the given timeframe. Additionally, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases. Another, driving factor for extracorporeal membrane oxygenation market is high adoption rate of ECMO technique for lung transplantation. Thus, increasing awareness about extracorporeal membrane oxygenation technique among the patients and in hospitals will provide market players with better opportunity in the future.
High treatment cost of extracorporeal membrane oxygenation (ECMO) and lack of skilled medical practitioners will hamper the market growth over the coming years. In addition, high risk of complications such as infections, excessive bleeding, formation of blood clots and strokes due to use of ECMO system will restrain business growth to certain extent.
Veno-venous ECMO held over USD 105.0 million in the year 2018. Rising incidence of acute respiratory disease will augment the growth of veno-venous market. The veno venous ECMO offers complete respiratory support, low recirculation rate and less complications such as reduced bleeding. With successful application during treatment of H1N1 epidemic veno-venous technique is gaining popularity among the market players, thereby stimulating industry growth.
Rising use of ECMO in respiratory disease held substantial market share in 2018 with a total value of around USD 175 million. According to the WHO, asthma causes more than 1,80,000 deaths annually. The major share of this segment is attributed to increasing cases of pulmonary diseases, lung cancer and respiratory failure along with rising awareness about ECMO procedure.
Adult patient population segment will expand at 4.6% CAGR during the given timeline. Rising number of adults suffering from respiratory conditions especially in the emerging economies will act as primary factor for segmental growth. Tuberculosis is one of the leading causes of death among adults. According to WHO, mortality rate is 10 times higher in people more than 60 years than in people aged between 15 to 59. Thus, increasing cases of acute respiratory disorder and growing geriatric population base will play a major role towards growth of extracorporeal membrane oxygenation market worldwide.
Canada accounted for around 15% of North America ECMO market in 2018. Rising prevalence of cardiovascular diseases, advanced healthcare infrastructure and presence of skilled healthcare professionals in the country will lead to growth of Canada ECMO systems market during the projected period.
UK extracorporeal membrane oxygenation market was valued over USD 15.0 million in the year 2018. According to official statistics, respiratory disease is the third leading cause of death in the country. The economic burden of all lung conditions is around USD 12 billion annually in the UK. Therefore, rising incidence of respiratory disorders and growing awareness about ECMO procedure will propel market growth over the projected timeframe.
Some of the notable industry players are Medtronic, Getinge, Terumo, Abbott, LivaNova, and Alung Technologies, among others. Strategic collaborations and launch of advanced ECMO devices are the major strategies adopted by market players to strengthen their market position.
Table of Contents
Chapter 1. Methodology
- 1.1. Methodology
- 1.2. Market definitions
- 1.3. Forecast parameters
- 1.4. Data sources
- 1.4.1. Secondary
- 1.4.1.1. Paid sources
- 1.4.1.2. Unpaid sources
- 1.4.2. Primary
Chapter 2. Executive Summary
- 2.1. Global extracorporeal membrane oxygenation industry 360 degree synopsis, 2014 - 2025
- 2.1.1. Business trends
- 2.1.2. Modality trends
- 2.1.3. Application trends
- 2.1.4. Patient population trends
- 2.1.5. Regional trends
Chapter 3. Extracorporeal Membrane Oxygenation Industry Insights
- 3.1. Industry segmentation
- 3.2. Industry landscape, 2014 - 2025
- 3.3. Industry impact forces
- 3.3.1. Growth drivers
- 3.3.1.1. Increase in cases of cardiopulmonary diseases and respiratory failure in Asia Pacific
- 3.3.1.2. Technological advancements in ECMO device in North America
- 3.3.1.3. Rising patient awareness about benefits delivered by extracorporeal membrane oxygenation device in Latin America
- 3.3.1.4. Rising government initiatives and programs in Europe
- 3.3.2. Industry pitfalls & challenges
- 3.3.2.1. High costs of equipment
- 3.3.2.2. Dearth of skilled professionals
- 3.3.2.3. Risks related to ECMO device
- 3.4. Growth potential analysis
- 3.4.1. By modality
- 3.4.2. By application
- 3.4.3. By patient population
- 3.5. Regulatory landscape
- 3.6. Porter's analysis
- 3.7. Competitive landscape, 2018
- 3.7.1. Strategy dashboard
- 3.8. PESTEL analysis
Chapter 4. Extracorporeal Membrane Oxygenation Market, By Modality
- 4.1. Key segment trends
- 4.2. Venoarterial (VA)
- 4.2.1. Market size, by region, 2014 - 2025
- 4.3. Veno-venous (VV)
- 4.3.1. Market size, by region, 2014 - 2025
- 4.4. Arteriovenous (AV)
- 4.4.1. Market size, by region, 2014 - 2025
Chapter 5. Extracorporeal Membrane Oxygenation Market, By Application
- 5.1. Key segment trends
- 5.2. Cardiac diseases
- 5.2.1. Market size, by region, 2014 - 2025
- 5.3. Respiratory diseases
- 5.3.1. Market size, by region, 2014 - 2025
- 5.4. Extracorporeal cardiopulmonary resuscitation (ECPR)
- 5.4.1. Market size, by region, 2014 - 2025
Chapter 6. Extracorporeal Membrane Oxygenation Market, By Patient Population
- 6.1. Key segment trends
- 6.2. Infant
- 6.2.1. Market size, by region, 2014 - 2025
- 6.3. Pediatric
- 6.3.1. Market size, by region, 2014 - 2025
- 6.4. Adult
- 6.4.1. Market size, by region, 2014 - 2025
Chapter 7. Extracorporeal Membrane Oxygenation Market, By Region
- 7.1. Key regional trends
- 7.2. North America
- 7.2.1. Market size, by country, 2014 - 2025
- 7.2.2. Market size, by modality, 2014 - 2025
- 7.2.3. Market size, by application, 2014 - 2025
- 7.2.4. Market size, by patient population, 2014 - 2025
- 7.2.5. U.S.
- 7.2.5.1. Market size, by modality, 2014 - 2025
- 7.2.5.2. Market size, by application, 2014 - 2025
- 7.2.5.3. Market size, by patient population, 2014 - 2025
- 7.2.6. Canada
- 7.2.6.1. Market size, by modality, 2014 - 2025
- 7.2.6.2. Market size, by application, 2014 - 2025
- 7.2.6.3. Market size, by patient population, 2014 - 2025
- 7.3. Europe
- 7.3.1. Market size, by country, 2014 - 2025
- 7.3.2. Market size, by modality, 2014 - 2025
- 7.3.3. Market size, by application, 2014 - 2025
- 7.3.4. Market size, by patient population, 2014 - 2025
- 7.3.5. Germany
- 7.3.5.1. Market size, by modality, 2014 - 2025
- 7.3.5.2. Market size, by application, 2014 - 2025
- 7.3.5.3. Market size, by patient population, 2014 - 2025
- 7.3.6. UK
- 7.3.6.1. Market size, by modality, 2014 - 2025
- 7.3.6.2. Market size, by application, 2014 - 2025
- 7.3.6.3. Market size, by patient population, 2014 - 2025
- 7.3.7. France
- 7.3.7.1. Market size, by modality, 2014 - 2025
- 7.3.7.2. Market size, by application, 2014 - 2025
- 7.3.7.3. Market size, by patient population, 2014 - 2025
- 7.3.8. Italy
- 7.3.8.1. Market size, by modality, 2014 - 2025
- 7.3.8.2. Market size, by application, 2014 - 2025
- 7.3.8.3. Market size, by patient population, 2014 - 2025
- 7.3.9. Spain
- 7.3.9.1. Market size, by modality, 2014 - 2025
- 7.3.9.2. Market size, by application, 2014 - 2025
- 7.3.9.3. Market size, by patient population, 2014 - 2025
- 7.4. Asia Pacific
- 7.4.1. Market size, by country, 2014 - 2025
- 7.4.2. Market size, by modality, 2014 - 2025
- 7.4.3. Market size, by application, 2014 - 2025
- 7.4.4. Market size, by patient population, 2014 - 2025
- 7.4.5. Japan
- 7.4.5.1. Market size, by modality, 2014 - 2025
- 7.4.5.2. Market size, by application, 2014 - 2025
- 7.4.5.3. Market size, by patient population, 2014 - 2025
- 7.4.6. China
- 7.4.6.1. Market size, by modality, 2014 - 2025
- 7.4.6.2. Market size, by application, 2014 - 2025
- 7.4.6.3. Market size, by patient population, 2014 - 2025
- 7.4.7. India
- 7.4.7.1. Market size, by modality, 2014 - 2025
- 7.4.7.2. Market size, by application, 2014 - 2025
- 7.4.7.3. Market size, by patient population, 2014 - 2025
- 7.4.8. Taiwan
- 7.4.8.1. Market size, by modality, 2014 - 2025
- 7.4.8.2. Market size, by application, 2014 - 2025
- 7.4.8.3. Market size, by patient population, 2014 - 2025
- 7.5. Latin America
- 7.5.1. Market size, by country, 2014 - 2025
- 7.5.2. Market size, by modality, 2014 - 2025
- 7.5.3. Market size, by application, 2014 - 2025
- 7.5.4. Market size, by patient population, 2014 - 2025
- 7.5.5. Brazil
- 7.5.5.1. Market size, by modality, 2014 - 2025
- 7.5.5.2. Market size, by application, 2014 - 2025
- 7.5.5.3. Market size, by patient population, 2014 - 2025
- 7.5.6. Mexico
- 7.5.6.1. Market size, by modality, 2014 - 2025
- 7.5.6.2. Market size, by application, 2014 - 2025
- 7.5.6.3. Market size, by patient population, 2014 - 2025
- 7.5.7. Argentina
- 7.5.7.1. Market size, by modality, 2014 - 2025
- 7.5.7.2. Market size, by application, 2014 - 2025
- 7.5.7.3. Market size, by patient population, 2014 - 2025
- 7.6. Middle East & Africa
- 7.6.1. Market size, by country, 2014 - 2025
- 7.6.2. Market size, by modality, 2014 - 2025
- 7.6.3. Market size, by application, 2014 - 2025
- 7.6.4. Market size, by patient population, 2014 - 2025
- 7.6.5. Saudi Arabia
- 7.6.5.1. Market size, by modality, 2014 - 2025
- 7.6.5.2. Market size, by application, 2014 - 2025
- 7.6.5.3. Market size, by patient population, 2014 - 2025
- 7.6.6. Qatar
- 7.6.6.1. Market size, by modality, 2014 - 2025
- 7.6.6.2. Market size, by application, 2014 - 2025
- 7.6.6.3. Market size, by patient population, 2014 - 2025
- 7.6.7. UAE
- 7.6.7.1. Market size, by modality, 2014 - 2025
- 7.6.7.2. Market size, by application, 2014 - 2025
- 7.6.7.3. Market size, by patient population, 2014 - 2025
- 7.6.8. South Africa
- 7.6.8.1. Market size, by modality, 2014 - 2025
- 7.6.8.2. Market size, by application, 2014 - 2025
- 7.6.8.3. Market size, by patient population, 2014 - 2025
Chapter 8. Company Profiles
- 8.1. Abbott Laboratories
- 8.1.1. Business overview
- 8.1.2. Financial data
- 8.1.3. Product landscape
- 8.1.4. Strategic outlook
- 8.1.5. SWOT analysis
- 8.2. Alung Technologies
- 8.2.1. Business overview
- 8.2.2. Financial data
- 8.2.3. Product landscape
- 8.2.4. Strategic outlook
- 8.2.5. SWOT analysis
- 8.3. Braile Biomedical
- 8.3.1. Business overview
- 8.3.2. Financial data
- 8.3.3. Product landscape
- 8.3.4. Strategic outlook
- 8.3.5. SWOT analysis
- 8.4. Edwards Lifesciences Corp
- 8.4.1. Business overview
- 8.4.2. Financial data
- 8.4.3. Product landscape
- 8.4.4. Strategic outlook
- 8.4.5. SWOT analysis
- 8.5. Elsius Biomedical Inc.
- 8.5.1. Business overview
- 8.5.2. Financial data
- 8.5.3. Product landscape
- 8.5.4. Strategic outlook
- 8.5.5. SWOT analysis
- 8.6. Eurosets Srl
- 8.6.1. Business overview
- 8.6.2. Financial data
- 8.6.3. Product landscape
- 8.6.4. Strategic outlook
- 8.6.5. SWOT analysis
- 8.7. Getinge Group
- 8.7.1. Business overview
- 8.7.2. Financial data
- 8.7.3. Product landscape
- 8.7.4. Strategic outlook
- 8.7.5. SWOT analysis
- 8.8. LivaNova PLC
- 8.8.1. Business overview
- 8.8.2. Financial data
- 8.8.3. Product landscape
- 8.8.4. Strategic outlook
- 8.8.5. SWOT analysis
- 8.9. Medtronic Inc.
- 8.9.1. Business overview
- 8.9.2. Financial data
- 8.9.3. Product landscape
- 8.9.4. Strategic outlook
- 8.9.5. SWOT analysis
- 8.10. MicroPort Scientific Corporation
- 8.10.1. Business overview
- 8.10.2. Financial data
- 8.10.3. Product landscape
- 8.10.4. Strategic outlook
- 8.10.5. SWOT analysis
- 8.11. Nipro Corporation
- 8.11.1. Business overview
- 8.11.2. Financial data
- 8.11.3. Product landscape
- 8.11.4. Strategic outlook
- 8.11.5. SWOT analysis
- 8.12. Origen Biomedical
- 8.12.1. Business overview
- 8.12.2. Financial data
- 8.12.3. Product landscape
- 8.12.4. Strategic outlook
- 8.12.5. SWOT analysis
- 8.13. Spectrum Medical
- 8.13.1. Business overview
- 8.13.2. Financial data
- 8.13.3. Product landscape
- 8.13.4. Strategic outlook
- 8.13.5. SWOT analysis
- 8.14. Terumo Corporation
- 8.14.1. Business overview
- 8.14.2. Financial data
- 8.14.3. Product landscape
- 8.14.4. Strategic outlook
- 8.14.5. SWOT analysis
